Adrian Brown PhD RD

> with a fasting circulating C-peptide of less than 600 pmol/L ..... how'd you pick this figure ? How many were excluded by this level ?

This was decided after discussion with our medical team as a safe level to avoid potential complications with insulin reduction. In advanced #T2D c-peptides can be very low so safety as taken very seriously.

Great work improving care of patients, but why pick energy restriction over carbohydrate restriction ?

Thanks @DoctorTro we hope that this data will help to offer choice for patients. IMO both methods can help this patient population. We choose #LED having reviewed the evidence & had experience using them, but #lowcarb could have been used @virtahealth have filled that gap nicely

Great study and congrats on the publication Will you be following up these participants?

Thanks, really glad you liked it. We do have data on a subset of patients at 24-months, this has yet to be analysed.

Nice study! Wondering why kg loss was the primary endpoint, not A1c change or other CVD risk factor. Is weight, independent from confounders, assoc. with mortality? Also, isn't it important when looking at reduced insulin burden that baseline A1c was lower in intervention group?

This was focusing on using LED to achieve weight loss in this group of patient who traditionally have struggled due to being on insulin. None of the baseline characteristics were statistically different incl. A1c.